Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 9, 2013, Pages 1047-1055

  O'Donnell, Margaret R ^a   Tallman, Martin S ^b   Abboud, Camille N ^c   Altman, Jessica K ^d   Appelbaum, Frederick R ^e   Arber, Daniel A ^f   Attar, Eyal ^g   Borate, Uma ^h   Coutre, Steven E ^f   Damon, Lloyd E ⁱ   Lancet, Jeffrey ^j   Maness, Lori J ^k   Marcucci, Guido ^l   Martin, Michael G ^m   Millenson, Michael M ⁿ   Moore, Joseph O ^o   Ravandi, Farhad ^p   Shami, Paul J ^q   Smith, B Douglas ^r   Stone, Richard M ^s   Strickland, Stephen A ^t   Wang, Eunice S ^u   Gregory, Kristina M ^v   Naganuma, Maoko ^v   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e USA   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁿ FOX CHASE CANCER CENTER   (United States)

^o DUKE CANCER INSTITUTE   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q UNIVERSITY OF UTAH   (United States)

^r JOHNS HOPKINS UNIVERSITY   (United States)

^s DANA FARBER CANCER INSTITUTE   (United States)

^t VANDERBILT INGRAM CANCER CENTER   (United States)

^u ROSWELL PARK CANCER INSTITUTE   (United States)

^v National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER RISK; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE;

EID: 84885093586     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0127     Document Type: Review

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. National Cancer Institute. SEER Stat Fact Sheets: Acute Myeloid Leukemia. Bethesda, MD: 2013. Available at: http://seer.cancer. gov/statfacts/html/amyl. html. Accessed May 7, 2013.
3. Arber DA, Vardiman JW, Brunning RD, et al. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:110-123.
4. Powell BL. Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther 2011;11:1317-1319.
5. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:391-399.
6. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248-1254.
7. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010;115:1690-1696.
8. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French- Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-1084. (Pubitemid 351213385)
9. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup study C9710. Blood 2010;116:3751-3757.
10. Sanz MA, Montesinos P, Rayon C, et al. Risk-Adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137-5146.
11. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-Adapted consolidation for adults patients younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116:3171-3179.
12. Ades L, Raffoux E, Chevret S, et al. Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group [abstract]. Blood 2010;116:Abstract 13.
13. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
14. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101:5328-5335. (Pubitemid 38481160)
15. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469-3473.
16. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-121.
17. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504-510.
18. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-4302. (Pubitemid 36001941)
19. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-1200. (Pubitemid 29380399)
20. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007;110:59-66. (Pubitemid 47026819)
21. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011;117:4716-4725.
22. Avvisati G, Petti M, Lo Coco F, et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood 2003;102:142a.